Israel's Compugen Ltd., a clinical-stage cancer immunotherapy company, is expanding its clinical collaboration agreement with Bristol Myers Squibb, Compugen announced Monday.
Follow Israel Hayom on Facebook and Twitter
Under the amended agreement, Bristol Myers Squibb will supply Opdivo (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study designed to assess COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo in selected cancer indications. Study initiation is expected in the second quarter of 2021.
"We are excited to further expand our clinical program evaluating COM701, our first-in-class anti PVRIG inhibitor," said Compugen President and CEO Anat Cohen-Dayag, Ph.D.
"Bristol Myers Squibb continues to be a valued partner for our COM701 clinical program as we advance the immunotherapy treatment landscape of patients with cancer," said Cohen-Dayag.
